Alzheimer Center Amsterdam, Neurology, Amsterdam University Medical Center, De Boelelaan 1118, Amsterdam, 1081 HZ, The Netherlands.
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
Alzheimers Res Ther. 2024 Aug 1;16(1):176. doi: 10.1186/s13195-024-01543-3.
Digital speech assessment has potential relevance in the earliest, preclinical stages of Alzheimer's disease (AD). We evaluated the feasibility, test-retest reliability, and association with AD-related amyloid-beta (Aβ) pathology of speech acoustics measured over multiple assessments in a remote setting.
Fifty cognitively unimpaired adults (Age 68 ± 6.2 years, 58% female, 46% Aβ-positive) completed remote, tablet-based speech assessments (i.e., picture description, journal-prompt storytelling, verbal fluency tasks) for five days. The testing paradigm was repeated after 2-3 weeks. Acoustic speech features were automatically extracted from the voice recordings, and mean scores were calculated over the 5-day period. We assessed feasibility by adherence rates and usability ratings on the System Usability Scale (SUS) questionnaire. Test-retest reliability was examined with intraclass correlation coefficients (ICCs). We investigated the associations between acoustic features and Aβ-pathology, using linear regression models, adjusted for age, sex and education.
The speech assessment was feasible, indicated by 91.6% adherence and usability scores of 86.0 ± 9.9. High reliability (ICC ≥ 0.75) was found across averaged speech samples. Aβ-positive individuals displayed a higher pause-to-word ratio in picture description (B = -0.05, p = 0.040) and journal-prompt storytelling (B = -0.07, p = 0.032) than Aβ-negative individuals, although this effect lost significance after correction for multiple testing.
Our findings support the feasibility and reliability of multi-day remote assessment of speech acoustics in cognitively unimpaired individuals with and without Aβ-pathology, which lays the foundation for the use of speech biomarkers in the context of early AD.
数字语音评估在阿尔茨海默病(AD)的最早、临床前阶段具有潜在相关性。我们评估了在远程环境中多次评估中测量的语音声学的可行性、测试-重测信度以及与 AD 相关的淀粉样蛋白-β(Aβ)病理学的相关性。
50 名认知正常的成年人(年龄 68±6.2 岁,58%为女性,46%为 Aβ 阳性)完成了为期五天的基于平板电脑的远程语音评估(即图片描述、日记提示讲故事、言语流畅性任务)。在 2-3 周后重复测试范式。从语音记录中自动提取语音特征,并计算 5 天期间的平均分数。我们通过系统可用性量表(SUS)问卷上的依从率和可用性评分来评估可行性。使用组内相关系数(ICC)来检查测试-重测信度。我们使用线性回归模型,调整年龄、性别和教育,研究了语音特征与 Aβ 病理学之间的相关性。
该语音评估是可行的,91.6%的参与者完成了测试,SUS 问卷的平均评分为 86.0±9.9。在平均语音样本中发现了高可靠性(ICC≥0.75)。与 Aβ 阴性个体相比,Aβ 阳性个体在图片描述(B=-0.05,p=0.040)和日记提示讲故事(B=-0.07,p=0.032)中停顿与单词的比例更高,尽管在进行多次测试校正后,这种效应失去了显著性。
我们的研究结果支持在认知正常的个体中,使用具有和不具有 Aβ 病理学的多日远程语音声学评估的可行性和可靠性,为在早期 AD 背景下使用语音生物标志物奠定了基础。